



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07C 32/300	A2	(11) International Publication Number: WO 00/23407 (43) International Publication Date: 27 April 2000 (27.04.00)
<p>(21) International Application Number: PCT/GB99/03420</p> <p>(22) International Filing Date: 15 October 1999 (15.10.99)</p> <p>(30) Priority Data: 9822473.6 16 October 1998 (16.10.98) GB</p> <p>(71) Applicants (for all designated States except US): GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB). THE UNIVERSITY OF SOUTH CAROLINA [US/US]; Office of Technology Transfer, Byrnes Building, Suite 501, Columbia, SC 29208 (US).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): BROWN, Peter, Jonathan [GB/US]; Glaxo Wellcome Inc., Five Moore Drive, Research Triangle Park, NC 27709 (US). CHAPMAN, James, Mood [US/US]; Dept. of Basic Pharmaceutical Sciences, College of Pharmacy, University of South Carolina, Columbia, SC 29208 (US). OPLINGER, Jeffrey, Alan [US/US]; Glaxo Wellcome Inc., Five Moore Drive, Research Triangle Park, NC 27709 (US). STUART, Ludwig, William [US/US]; Glaxo Wellcome Inc., Five Moore Drive, Research Triangle Park, NC 27709 (US). WILLSON, Timothy, Mark [GB/US]; Glaxo Wellcome Inc., Five Moore Drive, Research Trian-</p>	<p>gle Park, NC 27709 (US). WU, Zhengdong [CN/US]; 1086 King Road, DR218, Malvern, PA 19355 (US).</p> <p>(74) Agent: LEAROYD, Stephanie, Anne; Glaxo Wellcome plc, Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).</p> <p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published Without international search report and to be republished upon receipt of that report.</p>	
<p>(54) Title: CHEMICAL COMPOUNDS</p> <div data-bbox="423 1203 1081 1409"> <p style="text-align: right;">(1)</p> </div> <p>(57) Abstract</p> <p>Novel compounds of Formula (1) and esters, salts, and physiologically functional derivatives thereof are disclosed. Methods for preparing and using the compounds are also disclosed. Many of these compounds are selective activators of PPAR alpha. The compounds are particularly useful for treating obesity.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

5

CHEMICAL COMPOUNDSField of the Invention

The present invention relates to certain novel PPAR alpha activating compounds, processes for their preparation, pharmaceutical compositions
10 containing the compounds, and uses of the compounds as therapeutic agents.


Obesity can be described as a state of excessive accumulation of body fat, and is widely considered to be a major public health problem. Treatment of obesity remains a problem.

15 Certain fibrate compounds are described in WO92/10468. Such compounds are said to be useful in the prophylaxis and treatment of atherosclerosis.

PCT publication WO95/18533 describes methods of identifying activators and antagonists of peroxisome proliferator activated receptor
20 ("PPAR") and activators of retinoic acid receptor gamma. The disclosure discusses treating obesity.

Brief Description of the Invention





Briefly, in one aspect, the present invention provides compounds of
25 Formula (1) and esters, salts, and physiologically functional derivatives thereof





30

wherein m is from 0 to 20, R⁶ is selected from the group consisting of hydrogen and

5



and R^8 is selected from the group consisting of



10

where y is 0, 1, or 2, each alk is independently hydrogen or alkyl group containing 1 to 6 carbon atoms, each R group is independently hydrogen, halogen, cyano, $-NO_2$, phenyl, straight or branched alkyl or fluoroalkyl containing 1 to 6 carbon atoms and which can contain hetero atoms such as nitrogen, oxygen, or sulfur and which can contain functional groups such as ketone or ester, cycloalkyl containing 3 to 7 carbon atoms, or two R groups bonded to adjacent carbon atoms can, together with the carbon atoms to which they are bonded, form an aliphatic or aromatic ring or multi ring system, and where each depicted ring has no more than 3 alk groups or R groups that are not hydrogen. Preferably, the compounds of Formula (1) are PPAR alpha activating compounds.

20

The compounds of Formula (1) are generally PPAR alpha activating compounds, and therefore are useful in the treatment of a PPAR alpha

5 mediated disease, risk factor, or condition, in particular, obesity and
dyslipidemia. Therefore, in another aspect of the invention there is provided a
method of treating a PPAR alpha mediated disease, risk factor, or condition,
in particular obesity and dyslipidemia, comprising administering to an
individual in need thereof a therapeutically effective amount of a PPAR alpha
10 activating compound of Formula (1). The invention further provides the use of
a PPAR alpha activating compound of Formula (1) for the manufacture of a
medicament for the treatment of a PPAR alpha mediated disease, risk factor,
or condition, in particular obesity and dyslipidemia.

The invention further provides compounds of Formula (1) for use in
15 therapy, and pharmaceutical compositions comprising a compound of
Formula (1).

The invention also provides methods for preparing the compounds and
pharmaceutical compositions of the invention.

As used herein, unless otherwise indicated, the term alkyl or words
20 containing the terms such as fluoroalkyl, can be either straight chain or
branched chain. For example, a 3-carbon alkyl group can be either n-propyl
or i-propyl.

Detailed Description of the Invention

25 Preferably, the compounds of Formula (1) are PPAR alpha activating
compounds. More preferable compounds are those that, in addition to being PPAR
alpha activating compounds, are selective activators of PPAR alpha. By "PPAR
activating compound", or "PPAR activator", or the like, is meant those compounds
which achieve 50% activation of human PPAR ("hPPAR") alpha (in the Transfection
30 assay described below) at concentrations of 10^{-5} M or less, as exemplified in the
working examples. By selective, is meant those compounds which selectively
activate PPAR alpha over PPAR gamma such that the ratio

$$\frac{EC_{50} \text{ PPAR Gamma}}{EC_{50} \text{ PPAR Alpha}}$$

35 is at least 10, as exemplified in the working examples. Most preferred are those
compounds such that this ratio is at least 100.

5

Preferably, each R^6 and R^8 has no more than 2 R groups and no more than 2 alk groups that are other than hydrogen. Most preferably, all R groups and all alk groups are hydrogen.

Particularly preferred compounds are those where y is 0, m is from 0 to 6, and each alk and each R group is hydrogen.

Examples of suitable compounds of Formula (1) are

2-(4-(2-(1-(4-Biphenylethyl)-3-cyclohexylureido)ethyl)phenylthio)-2-methylpropionic acid

2-(4-(2-(1-(2-(4-Morpholinophenyl)ethyl)-3-cyclohexylureido)ethyl)phenylthio)-2-methylpropionic acid

2-(4-(2-(1-(Cyclohexanebutyl)-3-cyclohexylureido)ethyl)phenylthio)-2-methylpropionic acid

2-(4-(2-(1-Heptyl-3-(2,4-difluorophenyl)ureido)ethyl)phenylthio)-2-methylpropionic acid

2-(4-(2-(1-(2-Chloro-4-(2-trifluoromethylphenyl)phenylmethyl)-3-(cyclohexyl)ureido)ethyl)phenylthio)-2-methylpropionic acid

and esters, salts, and physiologically functional derivatives thereof.

Particularly preferred compounds of Formula (1) are




2-(4-(2-(1-(4-Biphenylethyl)-3-cyclohexylureido)ethyl)phenylthio)-2-methylpropionic acid

2-(4-(2-(1-(2-(4-Morpholinophenyl)ethyl)-3-cyclohexylureido)ethyl)phenylthio)-2-methylpropionic acid

2-(4-(2-(1-(Cyclohexanebutyl)-3-cyclohexylureido)ethyl)phenylthio)-2-methylpropionic acid

and esters, salts, and physiologically functional derivatives thereof.

The compounds of this invention can be prepared in a variety of ways. For example, the compounds of Formula (1) can be prepared by reacting the compounds of Formulas (2), (3), and (4),



5 to give compounds of the invention of Formula (1) wherein R^6 , R^8 , and m are as defined above. Synthetic routes will also be illustrated in the working examples below.

The compounds of the present invention may be utilized in the form of a pharmaceutically acceptable salt or solvate thereof. Preferred salts of
10 compounds of Formula (1) are those that are physiologically acceptable. However, non-physiologically acceptable salts are within the scope of the present invention for use as intermediates in the preparation of the compounds of the invention and their physiologically acceptable salts and physiologically functional derivatives.

15 The "physiologically functional derivatives" referred to herein are compounds which are converted in vivo to a compound of Formula (1) or one of its physiologically acceptable salts.

Many of the compounds of this invention will contain one or more stereocenters. The present invention includes all possible stereoisomers,
20 tautomers, and geometric isomers of the compounds, including optically enriched compositions as well as the racemic mixtures. When an enantiomerically enriched composition is desired, it may be obtained either by resolution of the final product or by stereospecific synthesis from either isomerically pure starting material or any convenient intermediate. Resolution
25 of the final product, an intermediate, or a starting material may be effected by any suitable method. See, for example, Stereochemistry of Carbon Compounds, by E. L. Eliel (Mcgraw Hill, 1962) and Tables of Resolving Agents, by S.H. Wilen.

Reference to "treatment" includes prophylaxis as well as the treatment
30 of established of established diseases or symptoms. Moreover, it will be appreciated that the amount of a compound of the invention required for use in treatment will vary with the nature of the condition being treated and the age and the condition of the patient and will be ultimately at the discretion of that attendant physician or veterinarian.

35 PPAR alpha, gamma, and delta are recognized subtypes of PPARs. The PPARs are known to bind to their target genes as heterodimers with RXR. The

5 present invention provides PPAR alpha activating compounds for use in the treatment of obesity, dyslipidemia, and other PPAR alpha mediated diseases, conditions, or risk factors. More particularly, the present invention provides PPAR alpha activators useful in the treatment of Alzheimer's disease, atherosclerosis, obesity, inflammation, cancer, psoriasis, pancreatitis, and various disease risk
10 factors. Most preferably the PPAR alpha activators are selective. Disease risk factors may include dyslipidemia, hypertriglyceridemia, hyperlipidemia, and hypercholesterolemia. See, for example, K.M. Anderson, et al., *An Updated Coronary Risk Profile*, AHA Medical/Scientific Statement Science Advisory, vol. 83, pp 356-362 (1991), W.P. Castilli, *The Triglyceride Issue: A View From Farmingham*,
15 Am. Heart J., vol. 112, pp 432-437 (1986), M. Austin, *Plasma Triglyceride and Coronary Heart Disease*, Arteriosclerosis and Thrombosis, vol. 11, pp 2-14 (1991), and J.J. Genest, et al., *Prevalence of Familial Lipoprotein Disorders in Patients With Premature Coronary Artery Disease*, vol. 85, pp 2025-2033 (1992). PPAR Alpha agonists have been shown to have antitumor activity. See, for example, Samid et al,
20 Biochem. Pharmacol. (1996) 52, 659-667. PPAR Alpha agonists have been shown to have antiinflammatory activity. See, for example, Wahli et. al., Nature (1996) 384, 39-43. PPAR Alpha agonists have been shown to have antiatherosclerotic activity. See, for example, Staels et. al., Nature (1998) p790.

A recognized clinical and epidemiological measure for the classification
25 of obesity is the Body Mass Index (BMI) which is defined as weight in kilograms divided by the square of height in meters. Typically, a BMI of 25-30 is considered as overweight and >30 as obese. Treatment according to the present invention generally refers to a lowering of BMI to less than about 29 to 31. It will however be appreciated by persons skilled in the art that obesity
30 is inherently difficult to classify, and that the cut-off point for the definition of obesity is necessarily arbitrary, in part because body fatness is a continuum. However, in general terms treatment according to the present invention desirably prevents or alleviates obesity to an extent whereby there is no longer a significant health risk to the patient.

35 The amount of a PPAR alpha activator which is required to achieve the desired biological effect will, of course, depend on a number of factors, for

5 example, the mode of administration and the precise clinical condition of the recipient. In general, the daily dose will be in the range of 0.01mg - 1g/kg, typically 0.1 - 100mg/kg. An intravenous dose may, for example, be in the range of 0.001mg to 0.1g/kg, typically 0.01mg to 10mg/kg, which may conveniently be administered as an infusion of from 0.1 μ g to 1mg, per
10 minute. Infusion fluids suitable for this purpose may contain, for example, from 0.01 μ g to 0.1mg, per milliliter. Unit doses may contain, for example, from 0.01 μ g to 1g of a PPAR alpha activator. Thus ampoules for injection may contain, for example, from 0.01 μ g to 0.1g and orally administrable unit dose formulations, such as tablets or capsules, may contain, for example, from
15 0.1mg to 1g.

A compound of this invention may be employed in the treatment of a disease or condition as the compound per se, but is preferably presented with an acceptable carrier in the form of a pharmaceutical formulation. The carrier must, of course, be acceptable in the sense of being compatible with the
20 other ingredients of the formulation and must not be deleterious to the recipient. The carrier may be a solid or a liquid, or both, and is preferably formulated with the activator as a unit-dose formulation, for example, a tablet, which may contain from 0.05% to 95% by weight of the activator.

The formulations include those suitable for oral, rectal, topical, buccal
25 (e.g. sub-lingual) and parenteral (e.g. subcutaneous, intramuscular, intradermal or intravenous) administration.

Formulations suitable for oral administration may be presented in discrete units, such as capsules, cachets, lozenges or tablets, each containing a predetermined amount of a PPAR alpha activator; as a powder
30 or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water or water-in-oil emulsion. In general, the formulations are prepared by uniformly and intimately admixing the active PPAR alpha activator with a liquid or finely divided solid carrier, or both, and then, if necessary, shaping the product. For example, a tablet may be
35 prepared by compressing or molding a powder or granules of the PPAR alpha activator optionally with one or more accessory ingredients. Compressed

5 tablets may be prepared by compressing, in a suitable machine, the compound in a free-flowing form, such as a powder or granules optionally mixed with a binder, lubricant, inert diluent and/or surface active/dispersing agent(s). Molded tablets may be made by molding, in a suitable machine, the powdered compound moistened with an inert liquid diluent.

10 Formulations suitable for buccal (sub-lingual) administration include lozenges comprising a PPAR alpha activator in a flavored base, usually sucrose and acacia or tragacanth, and pastilles comprising the activator in an inert base such as gelatin and glycerin or sucrose and acacia.

Formulations of the present invention suitable for parenteral
15 administration conveniently comprise sterile aqueous preparations of a PPAR alpha activator, preferably isotonic with the blood of the intended recipient. These preparations are preferably administered intravenously, although administration may also be effected by means of subcutaneous, intramuscular, or intradermal injection. Such preparations may conveniently
20 be prepared by admixing the activator with water and rendering the resulting solution sterile and isotonic with the blood. Injectable compositions according to the invention will generally contain from 0.1 to 5% w/w of the activator.

Formulations suitable for rectal administration are preferably presented as unit-dose suppositories. These may be prepared by admixing a PPAR
25 alpha activator with one or more conventional solid carriers, for example, cocoa butter, and then shaping the resulting mixture.

Formulations suitable for topical application to the skin preferably take the form of an ointment, cream, lotion, paste, gel, spray, aerosol, or oil. Carriers which may be used include Vaseline, lanolin, polyethylene glycols,
30 alcohols, and combinations of two or more thereof. The PPAR alpha activator is generally present at a concentration of from 0.1 to 15% w/w of the composition, for example, from 0.5 to 2%.

Experimental

35 The following examples are given in illustration of, but not limitation of, the invention. Each of the following Examples of the invention showed 50%

5 activation of hPPAR alpha at concentration of 10^{-5} M or less and are therefore, activators of hPPAR alpha. It is possible to prepare a large variety of the compounds of Formula (1) using standard solid phase synthetic methods such as those illustrated in the following working examples. The prepared compounds can then readily be screened for activity and selectivity using the
10 Transfection assay described below. By using these techniques, one can readily determine which compounds of Formula (1) are activators of PPAR alpha and which compounds of Formula (1) are selective activators of PPAR alpha. In addition, the highly efficient Binding assay described below can be used to quickly pre-screen large numbers of compounds and those
15 compounds that are shown to bind can then be screened for activity and selectivity.

Intermediate 1

t-Butyl 2-(4-bromophenylthio)-2-methylpropionate

20 A mixture of 4-bromothiophenol (100 g; 0.53 mole) and potassium hydroxide (29.5 g; 0.53 mole) in ethanol (1000 mL) was stirred until all material had dissolved. t-Butyl 2-bromoisobutyrate (117.6 g; 0.53 mole) was added dropwise over 30 min, keeping the temperature below 55°C. The resulting mixture was heated at reflux for 1 h, then cooled to 23°C. The precipitate (KBr) was removed by filtration and the
25 solvent evaporated. The residue was partitioned between water (1000 mL) and methylene chloride (500 mL) and the organic layer was separated, dried (Na_2SO_4) and evaporated to afford a white solid. Crystallization from hexane gave a white solid (119.85 g; 68%).

$^1\text{H-NMR}$ (CDCl_3) δ 7.41 (d, 2H, $J=7.5$ Hz), 7.35 (d, 2H, $J=7.5$ Hz), 1.40 (s, 15H).

Intermediate 2

t-Butyl 2-(4-(2-phthalimidoethenyl)phenylthio)-2-methylpropionate

A mixture of Intermediate 1 (50 g; 150 mmole), N-vinylphthalimide (27.2 g; 157 mmole), palladium acetate (1.68 g; 7.5 mmole), tri-*o*-tolylphosphine (3.07 g; 15
35 mmole) and triethylamine (42 mL) in a sealed tube was gently heated until all solids had dissolved then heated at 110°C for 15 h. The solvent was evaporated and the

5 residue partitioned between 2N HCl (300 mL) and ethyl acetate (300 mL) and filtered through celite. The organic layer was separated and the aqueous layer was extracted with ethyl acetate (100 mL). The combined organic layers were washed with brine (100 mL), dried (MgSO_4) and evaporated. The residue was purified by chromatography using EtOAc-Hexane- CH_2Cl_2 as eluent to afford a yellow solid
10 (43.14 g; 68%).

$^1\text{H-NMR}$ (CDCl_3) δ 7.90 (dd, 2H, $J=3.3$ Hz, $J'=5.4$ Hz), 7.76 (dd, 2H, $J=3.3$ Hz, $J'=5.4$ Hz), 7.64 (d, 1H, $J=15.3$ Hz), 7.48 (d, 2H, $J=8.4$ Hz), 7.41 (d, 2H, $J=8.4$ Hz), 7.37 (d, 1H, $J=15.3$ Hz), 1.45 (s, 6H), 1.43 (s, 9H).

15 Intermediate 3

t-Butyl 2-(4-(2-phthalimidoethyl)phenylthio)-2-methylpropionate

A solution of Intermediate 2 (43.1 g; 100 mmole) in THF (600 mL) was added to a suspension of Wilkinson's Catalyst (tris(triphenylphosphine)rhodium chloride) (5 g) in ethanol (100 mL) and the mixture stirred under an atmosphere of hydrogen (20
20 psi) for 5 h. The solvent was evaporated and the residue was purified by chromatography using EtOAc-Hexane- CH_2Cl_2 as eluent to afford a light brown solid (37g).

$^1\text{H-NMR}$ (CDCl_3) δ 7.82 (dd, 2H, $J=3.4$ Hz, $J'=5.6$ Hz), 7.70 (dd, 2H, $J=3.4$ Hz, $J'=5.6$ Hz), 7.41 (d, 2H, $J=8.0$ Hz), 7.20 (d, 2H, $J=8.0$ Hz), 3.91 (t, 2H, $J=7.8$ Hz), 2.98 (t,
25 2H, $J=7.8$ Hz), 1.40 (s, 9H), 1.39 (s, 6H).

Intermediate 4

t-Butyl 2-(4-(2-aminoethyl)phenylthio)-2-methylpropionate

A solution of Intermediate 3 (29.3 g; 69 mmole) in ethanol (500 mL) was
30 treated with hydrazine hydrate (20 g; 350 mmole) and the resulting mixture heated at reflux for 1 h and left to stand at 23°C for 15 h. The resultant solid was removed by filtration, the solvent evaporated, and the residue partitioned between 1N NaOH (150 mL) and ether (1300 mL). The organic layer was separated and washed with 1N NaOH (100 mL) and brine, dried (MgSO_4) and evaporated to afford an oil (19.9
35 g; 97%). $^1\text{H-NMR}$ (CDCl_3) δ 7.42 (d, 2H, $J=8.0$ Hz), 7.14 (d, 2H, $J=8.0$ Hz), 2.98 (br, 2H), 2.78 (t, 2H, $J=7.0$ Hz), 2.51 (br, 2H), 1.41 (s, 15H).

5

Intermediate 5**t-Butyl 2-(4-(2-(fluoren-9-ylmethyloxycarbonylaminoethyl)phenylthio)-2-methylpropionate**

A solution of Intermediate 4 (37.9 g; 130 mmole) in dioxane (100 mL) was
10 treated with a solution of sodium carbonate (13.6 g; 130 mmole) in water (200 mL)
followed by a slurry of Fmoc-OSu (43.3 g; 130 mmole) in dioxane (100 mL) and the
mixture was stirred at 23°C for 5 h. The organic solvent was evaporated and the
residue was acidified with 1N HCl. The organic material was extracted with CH₂Cl₂
(2 x 200 mL) and the combined organic layers were dried (Na₂SO₄) and evaporated.
15 The residue was purified by chromatography using 15 then 20% EtOAc-Hexane as
eluent to afford a gum (49.3 g; 74%). ¹H-NMR (CDCl₃) δ 7.77 (d, 2H, J=7.6 Hz),
7.57 (d, 2H, J=7.6 Hz), 7.44 (d, 2H, J=8.0 Hz), 7.31 (t, 2H, J=7.2 Hz), 7.13 (d, 2H,
J=8.0 Hz), 4.77 (m, 1H), 4.42 (d, 2H, J=6.8 Hz), 4.21 (t, 1H, J=6.8 Hz), 3.44 (q, 2H,
J=6.4 Hz), 2.81 (t, 2H, J=6.8 Hz), 1.44 (s, 6H), 1.42 (s, 9H).

20

Intermediate 6**2-(4-(2-(Fluoren-9-ylmethyloxycarbonylamino)ethyl)phenylthio)-2-methylpropionic acid**

A solution of Intermediate 5 (27.1 g; 52 mmole) in TFA (135 mL) and CH₂Cl₂
25 (135 mL) was stirred at 23°C for 5 h. The solvent was evaporated and the residue
dissolved in CH₂Cl₂ (200 mL) and washed with water (3 X 150 mL) and brine (2 X
100 mL), dried (MgSO₄) and evaporated to afford a low melting solid (22.9 g; 95%).
¹H-NMR (CDCl₃; complicated by rotamers) δ 9.25 (br, 1H), 7.76 (d, 2H, J=7.2 Hz),
7.56 (d, 2H, J=7.2 Hz), 7.46 (d, 2H, J=7.6 Hz), 7.39 (t, 2H, J=7.2 Hz), 7.30 (t, 2H,
30 J=7.2 Hz), 7.13 (d, 2H, J=7.6 Hz), 4.88 (br, 0.6H), 4.54 (br, 0.4H), 4.40 (d, 1.2H,
J=6.8 Hz), 4.19 (t, 0.8H, J=6.8 Hz), 3.43 (q, 1.2H, J=6.4 Hz), 3.17 (br, 0.8H), 2.80 (t,
1.2H, J=7.2 Hz), 2.53 (br, 0.8 Hz), 1.50 (s, 6H). Analysis Found: C, 68.97; H, 6.04;
N, 2.95. C₂₇H₂₇NO₄So0.5H₂O Requires: C, 68.91; H, 6.00; N, 2.98%.

35

Intermediate 7**Intermediate 6 loaded onto SASRIN® resin**

5 A solution of Intermediate 6 (9.66g, 20.93 mmole), 4-dimethylaminopyridine (256 mg; 2.093 mmole) and diisopropylcarbodiimide (2.635 g; 20.88 mmole) in CH_2Cl_2 (40 mL) was stirred at 23°C for 10 min. SASRIN® resin (4.7 g; 0.89 mmol/g; 4.186 mmole) was added and the resulting solution stirred at 23°C for 1.5 h. The resin was filtered and washed with CH_2Cl_2 (3 X 100 mL) then suspended in CH_2Cl_2 (40 mL) and treated with diisopropylethylamine (7 mL) and isovaleric anhydride (4
10 mL). After stirring at 23°C for 1 h, the resin was filtered and washed with CH_2Cl_2 (3 x 75 mL), DMF (3 x 75 mL), MeOH (3 x 75 mL) then CH_2Cl_2 (3 x 75 mL) and dried in vacuum. Resin loading was determined by standard Fmoc analysis (0.3-0.43 mmole/g).

15

Intermediate 8

t-Butyl N-(Cyclohexylbutanoyl)-2-(4-(2-aminoethyl)phenylthio)-2-methylpropionate

A solution of Intermediate 4 (77 g; 260.6 mmole) and cyclohexanebutanoic
20 acid (66.55 g; 390.9 mmole) in CH_2Cl_2 (500 mL) was treated with HOBToH₂O (20 g; 130.7 mmole) and diisopropylcarbodiimide (112.6 g; 521.2 mmole) and the resulting solution stirred at 23°C for 15 h. The solution was washed with saturated NaHCO_3 solution, 1N HCl and brine and the organic layer was dried (Na_2SO_4) and evaporated. The residue was purified by chromatography using 20% EtOAc-Hexane
25 as eluent to afford a white solid (100.7 g; 86%). ¹H-NMR (CDCl_3) δ 7.42 (d, 2H, J=8.0 Hz), 7.13 (d, 2H, J=8.0 Hz), 5.87 (br s, 1H), 3.49 (q, 2H, J=6.8 Hz), 2.81 (t, 2H, J=7.2 Hz), 2.12 (t, 2H, J=7.6 Hz), 1.73-1.52 (m, 7H), 1.41 (s, 15H), 1.26-1.07 (m, 6H), 0.84 (m, 2H).

Intermediate 9

t-Butyl 2-(4-(2-(Cyclohexylbutylamino)ethyl)phenylthio)-2-methylpropionate

A solution of Intermediate 8 (5 g; 5.92 mmole) in THF (50 mL) was treated with a 1M solution of borane in THF (40 mL; 40 mmole) and the mixture allowed to stand at 23°C for 15 h. Excess borane was destroyed by the careful addition of n-butanol (20
35 mL) and the resulting solution heated under reflux for 2h. The solvent was evaporated the residue was purified by chromatography using EtOAc then 10%

- 5 MeOH-EtOAc as eluent to afford an oil (3.78 g; 66%). ¹H-NMR (CDCl₃) δ 7.41 (d, 2H, J=8.0 Hz), 7.14 (d, 2H, J=8.0 Hz), 2.84 (m, 4H), 2.61 (t, 2H, J=7.2 Hz), 2.05 (br, 1H), 1.65 (m, 6H), 1.41 (s, 15H), 1.33-1.07 (m, 6H), 0.82 (m, 2H).

Intermediate 10

- 10 **t-Butyl 2-(4-(2-(1-(Cyclohexanebutyl)-3-cyclohexylureido)ethyl) phenylthio)-2-methylpropionate**

A solution of Intermediate 9 (5 g; 11.5 mmole) and cyclohexylisocyanate (1.73 g; 13.8 mmole) in CH₂Cl₂ (50 mL) was allowed to stand at 23°C for 18h. The solvent was evaporated and the residue purified by chromatography using 10% EtOAc-

- 15 Hexane as eluent to afford a white solid (5.3 g; 83%). ¹H-NMR (CDCl₃) δ 7.42 (d, 2H, J=8.1 Hz), 7.15 (d, 2H, J=8.1 Hz), 4.01 (d, 1H, J=7.8 Hz), 3.61 (m, 1H), 3.39 (t, 2H, J=7.5 Hz), 3.03 (t, 2H, J=7.5 Hz), 2.83 (t, 2H, J=7.5 Hz), 1.90 (m, 2H), 1.74-1.52 (m, 8H), 1.42 (s, 15H), 1.50-0.96 (m, 15H), 0.85 (m, 2H).

- 20 **Example 1**

2-(4-(2-(1-(Cyclohexanebutyl)-3-cyclohexylureido)ethyl) phenylthio)-2-methylpropionic acid

A solution of Intermediate 9 (5g; 8.96 mmole) in CH₂Cl₂ (40 mL) and TFA (40 mL) was allowed to stand at 23°C for 4 h. The solvent was evaporated to afford a semi-
25 solid, which was purified by chromatography using 5-20% MeOH-CH₂Cl₂ as eluent to afford a white solid (3.7 g; 82%). ¹H-NMR (CDCl₃) δ 9.05 (br, 1H), 7.44 (d, 2H, J=8.0 Hz), 7.15 (d, 2H, J=8.0 Hz), 4.28 (br, 1H), 3.63 (br s, 1H), 3.41 (t, 2H, J=7.4 Hz), 3.01 (t, 2H, J=7.6 Hz), 2.83 (t, 2H, J=7.2 Hz), 1.89 (m, 2H), 1.72-1.52 (m, 8H), 1.42 (s, 6H), 1.52-0.95 (m, 15H), 0.85 (m, 2H).

30

The following Example was prepared using the procedures outlined for the preparation of Example 1.

Example 2 2-(4-(2-(1-(4-Biphenylethyl)-3-cyclohexylureido)ethyl)phenylthio)-2-methylpropionic acid

5 **General Method****General solid phase synthesis method for preparation of 2-(4-(2-(Substituted ureido)ethyl)phenylthio)-2-methylpropionic acids**

40 mg of Intermediate 7 (0.43 mmol/g) was suspended in 1 mL of 20% piperidine in DMF for 30 min. The solution was drained and the resin was washed with DMF, CH₂Cl₂, MeOH, CH₂Cl₂, THF, and DMF. A solution of a carboxylic acid (1M in DMF, 0.17 mL), HOBT (1M in DMF, 0.17 mL), and DIC (1M in DMF, 0.17 mL) were added. The suspension was mixed and then stood at room temperature for 2 h. The solution was drained and the resin was washed with DMF, CH₂Cl₂, MeOH, CH₂Cl₂, and THF. A solution of BH₃oTHF (1M in THF, 0.52 mL) was added. The suspension was mixed and then stood at room temperature for 18 h. The solution was drained and the resin was washed with THF, CH₂Cl₂, DMF, MeOH, CH₂Cl₂ and DMF. A solution of an isocyanate (1M in DMF, 0.52 mL) was added. The suspension was mixed and then stood at room temperature for 18 h. The solution was drained and the resin was washed with DMF, CH₂Cl₂, MeOH, CH₂Cl₂, THF, and CH₂Cl₂. The resulting resin was suspended in 1 mL of 10% TFA in CH₂Cl₂ for 30 min. The solution was filtered and the filtrate evaporated to yield the 2-(4-(2-(Substituted ureido)ethyl)phenylthio)-2-methylpropionic acid.

Using the **General Method**, the following example was synthesized from Intermediate 7.

Example 3 2-(4-(2-(1-(2-Chloro-4-(2-trifluoromethylphenyl) phenylmethyl)-3-(cyclohexyl)ureido)ethyl)phenylthio)-2-methylpropionic acid

Intermediate 11**2-(4-(2-(Phenylmethyloxycarbonylamino)ethyl)phenoxy)-2-methylbutanoic acid**

A solution of 4-(2-(phenylmethyloxycarbonylamino)ethyl)phenol (5.74 g; 21.16 mmole) in 2-butanone (17 mL) and chloroform (6 g) was added dropwise to a mixture of sodium hydroxide (9.0 g; 225 mmole) and 2-butanone (67 mL) whilst keeping the reaction temperature below 30°C. The mixture was allowed to stir at 30°C for 4h. Ether (100 mL) was added and the resultant solid was collected by

5 filtration and washed with ether (100 mL). The solid was dissolved in water (70 mL) and any residual ether removed by evaporation. 1N Hydrochloric acid was added to adjust the pH to 1, and the resulting oil was extracted with dichloromethane (3 x 50 mL). The combined extracts were dried (Na₂SO₄) and evaporated to afford a yellow oil (3.82 g; 49%).

10 ¹H-NMR (CDCl₃) δ 7.26 (s, 5H), 7.09 (d, 2H, J=7.9 Hz), 6.88 (d, 2H, J=8.4 Hz), 5.09 (s, 2H), 4.75 (br s, 1H), 3.42-3.44 (m, 2H), 2.75 (t, 2H, J=6.7 Hz), 1.92-2.00 (m, 2H), 1.47 (s, 3H), 1.04 (t, 3H, J=2.6 Hz). Mass spectrometry ES⁻, m/e (M+H)⁺=372.

Intermediate 12

15 **Methyl 2-(4-(2-(phenylmethyloxycarbonylamino)ethyl)phenoxy)-2-methyl butyrate**

A solution of Intermediate 11 (2.0 g; 5.38 mmole) in dimethylformamide (12 mL) was treated with potassium carbonate (2.23 g; 16.14 mmole) and methyl iodide (1.54 g; 10.76 mmole) and the resulting mixture stirred at 23°C for 2h. The mixture
20 was filtered and the solid collected was washed with ethyl acetate (70 mL). The filtrate was washed with brine (4 x 50 mL), dried (Na₂SO₄) and evaporated. The residue was purified by chromatography on silica gel using hexane then 33% ethyl acetate-hexane as eluent to afford a colorless oil (1.27 g; 61%).

¹H-NMR (DMSO-d₆) δ 7.31 (m, 5H), 7.06 (d, 2H, J=8.4 Hz), 6.68 (d, 2H, J=8.4 Hz),
25 4.98 (s, 2H), 3.67 (s, 3H), 3.15 (m, 2H), 2.62 (t, 2H, J=7.1 Hz), 1.86 (m, 2H), 1.38 (s, 3H), 0.86 (t, 3H, J=7.3 Hz). Mass spectrometry ES⁺, m/e (M+Na)⁺ = 408.

Intermediate 13

Methyl 2-(4-(2-aminoethyl)phenoxy)-2-methyl butyrate acetate salt

30 A solution of Intermediate 12 (1.27 g; 3.29 mmole) in methanol (50 mL) and acetic acid (0.4 g) was treated with 10% palladium on carbon and shaken in a hydrogen atmosphere (50 psi) for 2h. The catalyst was filtered through celite and the solvent was evaporated to afford a yellow oil in quantitative yield (1.04 g).

¹H-NMR (CDCl₃): δ 7.06 (d, 2H, J=8.4 Hz), 6.77 (d, 2H, J=8.4 Hz), 6.70 (br s, 2H),
35 3.76 (s, 3H), 3.02 (br s, 2H), 2.82 (m, 2H), 1.99 (s, 3H), 1.92 (m, 2H), 1.48 (s, 3H), 0.96 (t, 3H, J=7.4 Hz). Mass spectrometry ES⁺, m/e (M+H)⁺=252.

5

Intermediate 14**Methyl 2-(4-(2-(2,4-dinitrophenylsulfonylamino)ethyl)phenoxy)-2-methyl butyrate**

A solution of Intermediate 13 (2 g; 6.42 mmole) in CH₂Cl₂ (40 mL) was treated with saturated sodium bicarbonate solution and the organic layer was separated. The aqueous layer was extracted with CH₂Cl₂ (5 x 50 mL) and the combined organic layers were dried (Na₂SO₄) and evaporated to afford the free base as a yellow oil (1.61 g; 100%). This was dissolved in CH₂Cl₂ (40 mL) and treated with pyridine (0.45 g; 5.61 mmole) and 2,4-dinitrophenylsulfonyl chloride (1.5 g; 5.61 mmole), and the mixture was allowed to stir at 23°C for 3h. Water (60 mL) was added and the organic layer separated, washed with water (3 X 40 mL) and saturated sodium bicarbonate (40 mL). The organic layer was dried (Na₂SO₄) and evaporated and the residue purified by chromatography using 15-20% EtOAc-Hexane as eluent to afford a light yellow solid (1.38 g; 51%).

¹H-NMR (CDCl₃): δ 8.63 (d, 1H, J=2.3 Hz), 8.49 (dd, 1H, J=8.4 Hz, J'=2.3 Hz), 8.07 (d, 1H, J=8.4 Hz), 6.89 (d, 2H, J=8.4 Hz), 6.54 (d, 2H, J=8.4 Hz), 5.34 (t, 1H, J=5.3 Hz), 3.78 (s, 3H), 3.48 (q, 2H, J=8.3 Hz), 2.75 (t, 2H, J=6.6 Hz), 1.92 (m, 2H), 1.42 (s, 3H), 0.93 (t, 3H, J=7.5 Hz).

25

Intermediate 15**Methyl 2-(4-(2-((2,4-dinitrophenylsulfonyl)(hept-2-en-1-yl))amino)ethyl)phenoxy)-2-methyl butyrate**

A solution of Intermediate 14 (315 mg; 0.654 mmole) in THF (15 mL) was treated with triphenylphosphine (343 mg; 1.308 mmole), hept-2-en-1-ol (150 mg; 1.308 mmole) and diethylazodicarboxylate (228 mg; 1.308 mmole) and the mixture allowed to stir at 23°C for 1h. The solvent was evaporated and the residue purified by chromatography using 10-15% EtOAc-Hexane as eluent to afford a semi-solid (400 mg; >100%). TLC and NMR shows that the desired compound is present along with 1,2-(diethoxycarbonyl)hydrazine.

35

Intermediate 16

5 **Methyl 2-(4-(2-(hept-2-en-1-ylamino)ethyl)phenoxy)-2-methyl butanoate**

A solution of Intermediate 15 (400 mg; 0.654 mmole) in CH₂Cl₂ (5 mL) was treated with triethylamine (132 mg; 1.308 mmole) and mercaptoacetic acid (78 mg; 0.85 mmole) and the mixture was allowed to stir at 23°C for 1h. The mixture was diluted with EtOAc (30 mL) and washed with water (3 X 20 mL) and aqueous sodium bicarbonate (30 mL). The organic layer was dried (Na₂SO₄), evaporated and the residue purified by chromatography using 10% EtOAc-Hexane then 50% EtOAc-Hexane then MeOH as eluent to afford an oil (177 mg; 78% from intermediate 24).
10 ¹H-NMR (CDCl₃): δ 7.06 (d, 2H, J=7.5 Hz), 6.75 (d, 2H, J=7.5 Hz), 5.59 (m, 2H), 3.76 (s, 3H), 3.30 (d, 2H, J=6.3 Hz), 2.87 (m, 4H), 1.96 (m, 4H), 1.47 (s, 3H), 1.28 (m, 15 5H), 0.96 (t, 3H, J=7.6 Hz), 0.86 (t, 3H, J=6.9 Hz).

Intermediate 17

Methyl 2-(4-(2-(1-hept-2-enyl-3-(2,4-difluorophenyl)ureido)ethyl)phenoxy)-2-methylbutyrate

20 A solution of Intermediate 16 (157 mg; 0.452 mmole) in methylene chloride (5 mL) was treated with 2,4-difluorophenylisocyanate (140 mg; 0.904 mmole) and the mixture allowed to stand at 23°C for 18h. The solvent was evaporated and the residue purified by chromatography on silica gel using 10% then 15% ethyl acetate-hexane as eluent to afford a yellow semi-solid (212 mg; 93%). Contaminated with
25 bis-(2,4-difluorophenyl)urea which co-elutes on column.
¹H-NMR (CDCl₃): δ 8.85 (br s, 1H), 8.02 (m, 1H), 7.09 (d, 2H, J=8.4 Hz), 6.77-6.90 (m, 4H), 5.70 (m, 1H), 5.36 (m, 1H), 3.76 (s, 3H), 3.54 (t, 2H, J=7.3 Hz), 2.84 (t, 2H, J=7.1 Hz), 1.55 (br s, 1H), 1.46 (s, 3H), 1.25-1.35 (m, 5H), 0.96 (t, 3H, J=7.3 Hz), 0.88 (t, 3H, J=7.4 Hz). Mass spectrometry CI/AP⁺, m/e (M+H)⁺=503.

30 **Radioligand Precursor**

2-(4-(2-(1-Hept-2-enyl-3-(2,4-difluorophenyl)ureido)ethyl) phenoxy)-2-methylbutanoic acid

A solution of Intermediate 17 (370 mg; 0.736 mmole) in methanol (15 mL)
35 was treated with 1N NaOH (7.5 mL) and the mixture heated under reflux for 2h. The mixture was acidified with 1N HCl and extracted with ethyl acetate (3 x 25 mL). The

5 combined organic layers were washed with brine, dried (Na_2SO_4) and evaporated. The residue was purified by chromatography on silica gel using 20% ethyl acetate-hexane then ethyl acetate as eluent to afford a tan oil (280 mg; 78%).

$^1\text{H-NMR}$ (CDCl_3) δ 7.95-8.09 (m, 1H), 7.14 (d, 2H, $J=7.1$ Hz), 6.90 (d, 2H, $J=7.4$ Hz), 6.81 (d, 2H, $J=5.2$ Hz), 5.66 (m, 1H), 5.37 (m, 1H), 3.56 (t, 2H, $J=7.4$ Hz), 2.87 (t, 2H, $J=7.4$ Hz), 2.00 (m, 4H), 1.44 (s, 3H), 1.27 (m, 6H), 1.03 (t, 3H, $J=7.3$ Hz), 0.88 (t, 3H, $J=7.3$ Hz). Mass spectrometry ES^- , m/e ($\text{M}+\text{H}$) $^+$ = 489.

Radioligand

15 2-(4-(2-(2,3-Ditritio-1-heptyl-3-(2,4-difluorophenyl)ureido)ethyl) phenoxy)-2-methylbutanoic acid

A solution of the Radioligand precursor (10 mg) in anhydrous DMF (3.5 mL) was transferred to a reaction vessel containing 10 % Pd/C (9.8 mg). The reaction vessel was evacuated and degassed via one freeze-thaw-evacuation cycle and then exposed to tritium gas (10.1 Ci). After 4h, the mixture was
20 filtered through celite, evaporated and the residue dissolved in acetonitrile. A portion of this solution (0.8 mL, 26.6 mCi) was purified by HPLC (Dynamax C8, 25 min gradient from 4:1 acetonitrile:0.1%TFA to 9:1 acetonitrile: 0.1% TFA, 235 nm). Fractions containing pure material were combined and evaporated under nitrogen. The residue was redissolved in acetonitrile to
25 provide a solution of the title compound (82.0 Ci/mmol, radiochemical purity, 99%).

The above Radioligand was used in the binding assay described below to show that compounds which were active in the transfection assay were also ligands for PPAR Alpha.

30

Cold Radioligand

2-(4-(2-(1-Heptyl-3-(2,4-difluorophenyl)ureido)ethyl) phenoxy)-2-methylbutanoic acid

A solution of the Radioligand precursor (10 mg) in anhydrous DMF (3.5
35 mL) was transferred to a reaction vessel containing 10 % Pd/C (9.8 mg). The reaction vessel was evacuated and degassed via one freeze-thaw-evacuation

- 5 cycle and then exposed to hydrogen gas. After 4h, the mixture was filtered through celite and evaporated. The residue was purified by chromatography using 2% MeOH/CH₂Cl₂ as eluent to afford a gum (7mg).

Intermediate 18

- 10 Tert-butyl-2-[4-(2-(2-(4-morpholinylphenyl)-1-oxoethyl)aminoethyl)phenylthio]-2-methyl propionate

- To a solution of Intermediate 4 (3.54 g, 12 mmol) and (4-morpholinylphenyl) acetic acid (3.1 g, 14 mmol) in CH₂Cl₂ (200 mL) was added 1-(3-dimethyl aminopropyl)-3-ethylcarbodiimide hydrochloride (2.7 g; 14 mmol). The mixture was stirred for 4 hr at 23 °C. After diluting with CH₂Cl₂ (200 mL), the solution was washed twice with water (100 mL), dried (Na₂SO₄), evaporated, and the residue purified by silica gel chromatography to yield a light tan-colored solid (4.5 g; 75%). Mass Spectrum (ES⁺) 499.1 (MH⁺, 60%), 521.1 (M+Na⁺, 100%); ¹H NMR (CDCl₃) δ 7.36 (d, 2H, J = 8.1 Hz), 7.05 (d, 2H, J = 8.6 Hz), 6.99 (d, 2H, J = 7.9 Hz), 6.84 (d, 2H, J = 8.5 Hz), 5.36 (br s, 1H), 3.87 (t, 4H, J=4.8 Hz), 3.45 (s, 2H), 3.42 (q, 2H, J = 6.4 Hz), 3.15 (t, 4H, J= 4.8 Hz), 2.72 (t, 2H, J = 7.0 Hz), 1.42 (s, 15H).

Intermediate 19

- 25 t-Butyl 2-[4-(2-(1-(2-(4-Morpholinophenyl)ethyl)-3-cyclohexylureido)ethyl)phenylthio]-2-methylpropionate

- To a 0 °C THF (75 mL) solution of Intermediate 18 (3.88 g, 7.78 mmol) was added of 1M BH₃.THF complex in THF (54.4 mL; 54.4 mmol). The solution was allowed to stir for 5h while gradually warming to 23 °C. After cooling to 0 °C, MeOH (50 mL)was added dropwise and the solution was concentrated to dryness. The resulting oil was refluxed for 30 min with n-butanol (50 mL) in the presence of 4 mL (excess) of cyclohexylisocyanate. Upon cooling and concentration, the crude product was purified by silica gel chromatography using 20%-80% EtOAc in Hexanes as eluent to yield a colorless, viscous oil (2.8 g; 60%). Mass Spectrum (ES⁺) 610.1 (MH⁺, 60%), 632.1 (M+Na⁺, 50%); ¹H NMR (d₆-DMSO) δ 7.33 (d, 2H, J=8.1 Hz), 7.18 (d,

5 2H, J=7.9 Hz), 7.02 (d, 2H, J=8.6 Hz), 6.82 (d, 2H, J=8.6 Hz), 5.63 (d, 1H, J=7.8 Hz), 3.69 (t, 4H, J=4.5 Hz), 3.4-3.2 (m, 5H plus water peak), 3.00 (t, 4H, J=4.5 Hz), 2.69 (t, 2H, J=7.2 Hz), 2.57 (t, 2H, J=7.2 Hz), 1.65 (m, 4H), 1.53 (d, 1H, J=12.7 Hz), 1.32 (s, 9H), 1.3 (s, 9H), 1.2-1.0 (m, 5H).

10 **Example 4**

2-(4-(2-(1-(2-(4-Morpholinophenyl)ethyl)-3-cyclohexylureido)ethyl)phenylthio)-2-methylpropionic acid

To a solution of Intermediate 19 (2.75 g, 4.5 mmol) in CH₂Cl₂ (50 mL) at 0 °C was added 60 mL of 1:1 TFA: CH₂Cl₂. The solution was stirred for 60
15 min, then warmed to 23°C and stirred an additional 60 min. After concentration to dryness, the crude product as a solution in MeOH/ CH₂Cl₂ was neutralized to pH = ~7 with NH₄OH/MeOH solution. The biphasic mixture was separated, the aqueous phase washed with CH₂Cl₂ and the combined organics dried (Na₂SO₄) and concentrated. Silica gel chromatography eluting
20 with CH₂Cl₂, then 1% -20% MeOH in CH₂Cl₂ gave a maroon-colored oil. A second flush through a short plug of silica gel with 10% MeOH in 1:1 EtOAc: CH₂Cl₂ removed most of the color to yield a light tan-colored foamy solid (2.05 g; 82%). Mass Spectrum (ES⁺) 554.1 (MH⁺, 100%), 576.1 (M+Na⁺, 90%); ¹H NMR (d₆-DMSO) δ 7.33 (d, 2H, J=8.0 Hz), 7.18 (d, 2H, J=8.0 Hz),
25 7.04 (d, 2H, J=8.6 Hz), 6.82 (d, 2H, J=8.2 Hz), 5.63 (d, 1H, J=7.7 Hz), 3.7 (t, 4H, J=4.7 Hz), 3.3 (t, 2H, J=7.6 Hz), 3.23 (t, 2H, J=7.5 Hz), 3.00 (t, 4H, J=4.6 Hz), 2.69 (t, 2H, J=7.5 Hz), 2.58 (t, 2H, J=7.4 Hz), 1.66 (m, 4H), 1.54 (d, 1H, J=12.7 Hz), 1.31 (s, 6H), 1.2-1.0 (m, 5H).

30 **Intermediate 20**

t-Butyl N-Heptanoyl-2-(4-(2-aminoethyl)phenylthio)-2-methylpropionate

A solution of Intermediate 4 (297 mg; 1.006 mmole) and heptanoic acid (196 mg; 1.51 mmole) in CH₂Cl₂ (7 mL) was treated with HOBToH₂O (77 mg; 0.5 mmole) and diisopropylcarbodiimide (253 mg; 2.012 mmole) and the resulting solution stirred
35 at 23°C for 15 h. The solution was washed with saturated NaHCO₃ solution, 1N HCl and brine and the organic layer was dried (Na₂SO₄) and evaporated. The

5 residue was purified by chromatography using 20% EtOAc-Hexane as eluent to afford a gum (241 mg). ¹H-NMR (CDCl₃) δ 7.37 (d, 2H, J=8.0 Hz), 7.07 (d, 2H, J=8.0 Hz), 5.35 (br s, 1H), 3.44 (m, 2H), 2.75 (t, 2H, J=7.0 Hz), 2.28 (t, 1H, J=7.5 Hz), 2.05 (t, 2H, J=7.7 Hz), 1.47-1.59 (m, 3H), 1.35 (m, 13H), 1.19 (m, 6H), 0.8 (m, 3H).

10 **Intermediate 21**

t-Butyl 2-(4-(2-(1-Heptyl-3-(2,4-difluorophenyl)ureido)ethyl)phenylthio)-2-methylpropionate

A solution of Intermediate 20 (241 mg; 0.592 mmole) in THF (5 mL) was treated with a 1M solution of borane in THF (4 mL; 4 mmole) and the mixture
15 allowed to stand at 23°C for 15 h. Excess borane was destroyed by the careful addition of methanol and the resulting solution heated under reflux for 30 min. The solvent was evaporated and the residue was dissolved in CH₂Cl₂ (5 mL) and treated with 2,4-difluorophenylisocyanate (184 mg; 1.184 mmole) and allowed to stand at 23°C for 15 h. The mixture was washed with 2N HCl and the organic layer was dried
20 (Na₂SO₄) and evaporated. The residue was purified by chromatography using EtOAc-Hexane as eluent to afford an oil (270 mg). ¹H-NMR (CDCl₃) δ 8.03 (m, 1H), 7.44 (d, 2H, J=8.2 Hz), 7.18 (d, 2H, J=7.8 Hz), 6.83 (m, 2H), 6.34 (br s, 1H), 3.52 (t, 2H, J=7.5 Hz), 3.19 (t, 2H, J=7.8 Hz), 2.92 (t, 2H, J=7.5 Hz), 1.59 (m, 2H), 1.41 (m, 13H), 1.3 (m, 9H), 0.88 (m, 3H).

25

Example 5

2-(4-(2-(1-Heptyl-3-(2,4-difluorophenyl)ureido)ethyl)phenylthio)-2-methylpropionic acid

A solution of Intermediate 21 (270 mg; 0.506 mmole) in CH₂Cl₂ (3 mL) and
30 TFA (3 mL) was allowed to stand at 23°C for 4 h. The solvent was evaporated to afford a semi-solid (240 mg). ¹H-NMR (CDCl₃) δ 7.99 (m, 1H), 7.45 (d, 2H, J=7.8 Hz), 7.20 (d, 2H, J=8.1 Hz), 6.82 (m, 2H), 6.34 (br s, 1H), 3.53 (t, 2H, J=7.5 Hz), 3.16 (t, 2H, J=7.6 Hz), 2.92 (t, 2H, J=7.4 Hz), 2.20 (br, 2H), 1.85 (br, 2H), 1.75-1.52 (m, 4H), 1.42 (s, 6H), 1.45-1.15 (m, 11H), 0.87 (t, 3H, J=6.8 Hz).

35

5

Binding Assay.

To generate a bacterial expression plasmid for the ligand binding domain of hPPAR alpha, cDNA encoding the hinge and ligand binding domains of hPPAR alpha (amino acids 167-468) was amplified by polymerase chain reaction and the amplified product inserted in frame into the pGEX-2T plasmid (Pharmacia). The amplified region of hPPAR alpha was sequence confirmed. GST-hPPAR alpha was expressed in BL21(DE3)plysS cells and extracts prepared by freeze-thawing the cells in Bacterial Lysis Buffer (10 mM Tris, pH 8.0, 250 mM KCl, 1 mM DTT, 1% Triton X-100) followed by centrifugation at 40,000 x g for 30 minutes. Glycerol was added to the bacterial extracts to a final concentration of 10%. Bacterial extracts were dialyzed extensively against Bacterial Lysis Buffer containing 10% glycerol. Binding assays included 50 µg of bacterial extracts (containing GST-hPPAR alpha), 60 nM Radioligand, and either 10 µM Cold Radioligand (or comparative example) or vehicle alone (0.1% DMSO, final concentration) in buffer containing 10 mM Tris (pH 8.0), 50 mM KCl, 10 mM DTT. Binding reactions were incubated at 4°C for 2-3 hr. Bound radioactivity was separated from free radioactivity by elution through 1 ml Sephadex G-25 protein desalting columns (Boehringer Mannheim). Bound radioactivity eluted in the column void volume and was quantitated by liquid scintillation counting.

Results (data represent the mean of assays performed in triplicate and are presented as dpm).

30	No competitor	140000
	+ 10 µM Cold Radioligand	25000
	Specific Binding	115000

Transfection Assay

35 **Plasmids:** GAL4-hPPAR alpha chimera and UAS-tk-SPAP reporters. The GAL4-hPPAR alpha and the GAL4-hPPAR gamma expression constructs contain the

5 translation initiation sequence and amino acids 1-76 of the glucocorticoid receptor fused to amino acids 1-147 of the yeast (*S.cerevisiae*) transcription factor GAL4 in the pSG5 expression vector (Stratagene). Amino acids 167-468 of hPPAR alpha or amino acids 195-475 of hPPAR gamma were amplified by polymerase chain reaction (PCR) using vent polymerase (New England Biolabs) and inserted C-
10 terminal to the GAL4 sequences. The UAS-tk-SPAP reporter contain 5 copies of the GAL4 binding site inserted into pG12-tk-SPAP (Berger et al, 1988).

Transfection assay: SPAP reporter. CV-1 cells were plated in DME medium supplemented with 10% delipidated fetal calf serum at a density of 2.4×10^4 cells per
15 well in a 96-well plate (Costar) 16-24 h before transfection. In general, 8.0 ng of reporter plasmid, 25.0 ng of β -galactosidase expression vector (pCH110, Pharmacia), and 2.0 ng of GAL4-hPPAR alpha or GAL4-hPPAR gamma expression vector were mixed with carrier DNA (pBluescript, Stratagene) to a total of 80 ng of DNA per well in a volume of 10ml optiMEM I medium (Life Technologies).
20 To this, a second mix, containing 9.3 ml optiMEM I medium and 0.7 ml of LIPOFECTAMINETM (Life Technologies), was added. After 30 min. an additional 80ml of optiMEM I medium were added and the combined mix was then applied to the cells. 16 h later the medium was exchanged to DME medium supplemented with 10% delipidated and heat inactivated fetal calf serum and the test compound at a
25 concentration of 10^{-5} M. After incubation for 24 h, SPAP activity and β -galactosidase activity were measured by directly adding to the medium 200ml substrate mix (16mM o-nitrophenyl β -D-galactopyranoside (Sigma), 120mM fluorescein diphosphate (Molecular Probes), 0.16% Triton X-100, 160mM diethanolamine pH9, 44.8mM NaCl, and 0.8mM $MgCl_2$). Alternatively, alkaline phosphatase and β -galactosidase
30 activities were measured separately using standard protocols. Briefly, cells were lysed by adding 25ml 0.5% Triton X-100 to the supernatant. To 40ml cell lysate, 200ml β -galactosidase substrate reagent (36mM o-nitrophenyl β -D-galactopyranoside, 1.25mM $MgCl_2$, 2.8mM NaCl, 4.4M β -mercaptoethanol) or 200ml alkaline phosphatase substrate reagent (2.5 mM p-nitrophenyl phosphate, 0.5 mM
35 $MgCl_2$, 28 mM NaCl, 1 M diethanolamine pH 9.85) were added and incubated for 1

- 5 h. Alkaline phosphatase activity was expressed as percent maximal induction obtained for reference compound BRL49653, normalized to β -galactosidase activity which served as internal control standard for transfection efficiency.

References; see, for example, Berger, J., et al., (1988), Gene 66, 1-10.

- Each of the five Examples showed 50% activation of hPPAR alpha at
10 concentrations of 10^{-5} M or less. These five examples also selectively activate PPAR alpha over PPAR gamma such that the activity ratio, as explained above, is at least 10. Examples 1, 2, and 3 had activity ratios greater than 100.

- The following rodent data was produced using Example 5. The
15 purpose of the experiment is to demonstrate that activators of PPAR alpha are useful for the treatment of obesity, and dyslipidemia.

Diet-Induced Model of Dyslipidemia

- Zucker lean male rats and Zucker fa/fa female rats were randomized
20 into 3 treatment groups. The randomization was based on serum triglyceride concentration after three months on the TEKLAD high fat diet. Dosing with Example 5 or the appropriate vehicle, by oral gavage, began after 4 months of high fat feeding. Plasma glucose, lactate, serum insulin and lipid concentrations were obtained weekly, beginning on day 7 through 48 after the initiation of therapy.
25 Metabolic data from each treatment group was collected weekly. Dexascan determinations of body mass composition obtained after 4 months on the high fat diet served as baseline. Changes in body mass composition due to therapy were determined by repeat measurements at the end of the study.

- 30 **Treatment Group A** Vehicle dosed twice a day (approximately 8 am and 4 pm).

Treatment Group B Example 5 (0.1 mg/kg) dosed twice a day.

Treatment Group C Example 5 (0.3 mg/kg) dosed twice a day.

35

The results are summarized in the following two tables.

5


Males (n=4)	Group	After 4 months on high-fat diet	Week 1	Week 4	Week 7
		Control	Drug Treatment		
	Vehicle	788	718	741	725
Triglycerides (mg/dL)	0.1 mg/kg	828	460	467	584
	0.3 mg/kg	926	527	174	219
	Vehicle	227	191	224	215
Cholesterol (mg/dL)	0.1 mg/kg	221	138	189	148
	0.3 mg/kg	235	138	174	151
	Vehicle	0.67	0.85	0.65	0.60
NEFA (m Eq/L)	0.1 mg/kg	0.72	0.73	0.57	0.58
	0.3 mg/kg	0.72	0.69	0.47	0.46
	Vehicle	621	610	610	632
Body Weight (g)	0.1 mg/kg	636	617	592	597
	0.3 mg/kg	639	608	577	565

5

Females (n=4)	Group	After 4 months on high-fat diet	Week 1	Week 4	Week 7
		Control	Drug Treatment		
	Vehicle	8222	5357	10414	5465
Triglycerides (mg/dL)	0.1 mg/kg	9310	2717	3913	2627
	0.3 mg/kg	9190	1627	687	538
	Vehicle	1670	1186	1319	923
Cholesterol (mg/dL)	0.1 mg/kg	1648	610	733	632
	0.3 mg/kg	1908	350	404	422
	Vehicle	11.10	6.78	2.79	3.77
NEFA (m Eq/L)	0.1 mg/kg	11.15	2.47	1.32	1.75
	0.3 mg/kg	13.06	1.45	0.59	0.53
	Vehicle	649	684	700	706
Body Weight (g)	0.1 mg/kg	665	721	723	710
	0.3 mg/kg	645	673	643	582





5 What is claimed is:

1. A compound of Formula (1), or an ester, salt, or physiologically functional derivative thereof





(1)

wherein m is from 0 to 20, R^6 is selected from the group consisting of hydrogen and



15 and R^8 is selected from the group consisting of



where y is 0, 1, or 2, each alk is independently hydrogen or alkyl group containing 1 to 6 carbon atoms, each R group is independently hydrogen,

- 5 halogen, cyano, -NO₂, phenyl, straight or branched alkyl or fluoroalkyl
containing 1 to 6 carbon atoms and which can contain hetero atoms such as
nitrogen, oxygen, or sulfur and which can contain functional groups such as
ketone or ester, cycloalkyl containing 3 to 7 carbon atoms, or two R groups
bonded to adjacent carbon atoms can, together with the carbon atoms to
10 which they are bonded, form an aliphatic or aromatic ring or multi ring system,
and where each depicted ring has no more than 3 alk groups or R groups that
are not hydrogen.
2. The compound of Claim 1 wherein said compound is an activator of PPAR
15 alpha.
3. The compound of Claim 1 wherein said compound is a selective activator
of PPAR alpha.
- 20 4. The compound of any of Claims 1-3 wherein each R⁶ and each R⁸ has no
more than 2 R groups and no more than 2 alk groups that are other than
hydrogen.
5. The compound of any of Claims 1-4 Claim wherein y is 0, m is from 0 to 6,
25 and each alk and each R group is hydrogen.
6. The compound of any of Claims 1-4 wherein said compound is
- 2-(4-(2-(1-(4-Biphenylethyl)-3-cyclohexylureido)ethyl)phenylthio)-2-
methylpropionic acid
- 2-(4-(2-(1-(2-(4-Morpholinophenyl)ethyl)-3-cyclohexylureido)ethyl)phenylthio)-2-
methylpropionic acid
- 2-(4-(2-(1-(Cyclohexanebutyl)-3-cyclohexylureido)ethyl)phenylthio)-2-
methylpropionic acid
- 2-(4-(2-(1-Heptyl-3-(2,4-difluorophenyl)ureido)ethyl)phenylthio)-2-
methylpropionic acid
- 2-(4-(2-(1-(2-Chloro-4-(2-trifluoromethylphenyl) phenylmethyl)-3-
(cyclohexyl)ureido)ethyl)phenylthio)-2-methylpropionic acid

- 5 or an ester, salt, or physiologically functional derivative thereof.
7. The compound of any of Claims 1-5 wherein said compound is
- 2-(4-(2-(1-(4-Biphenylethyl)-3-cyclohexylureido)ethyl)phenylthio)-2-methylpropionic acid
- 2-(4-(2-(1-(2-(4-Morpholinophenyl)ethyl)-3-cyclohexylureido)ethyl)phenylthio)-2-methylpropionic acid
- 2-(4-(2-(1-(Cyclohexanebutyl)-3-cyclohexylureido)ethyl)phenylthio)-2-methylpropionic acid
- or an ester, salt, or physiologically functional derivative thereof.
- 10 8. A compound according to any of Claims 1-7 for use in therapy.
9. A pharmaceutical composition comprising a compound according to any of Claims 1-7.
- 15 10. A method for treating obesity or dyslipidemia comprising administration of a compound of any of Claims 1-7.
11. The method of Claim 10 wherein said compound is coadministered with an RXR ligand.
- 20 12. A method for treating a PPAR alpha mediated disease, risk factor, or condition comprising administering an effective amount of a compound of any of Claims 1-7.
- 25 13. The method of Claim 12 wherein said disease, risk factor, or condition is, or is associated with Alzheimer's disease, obesity, dyslipidemia, atherosclerosis, or diabetes.

5 14. Use of a compound according to any of Claims 1-7 for the manufacture of
a medicament for the treatment of a PPAR alpha mediated disease, risk
factor, or condition.

15. Use according to Claim 14 wherein the disease, risk factor, or condition
10 is, or is associated with, Alzheimer's disease, obesity, dyslipidemia,
atherosclerosis, or diabetes.

16. Use of a compound according to any of Claims 1-7 for the manufacture of
a medicament for the treatment of obesity or dyslipidemia.

15

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07C 323/62, A61K 31/17, C07D 295/135		A3	(11) International Publication Number: WO 00/23407
			(43) International Publication Date: 27 April 2000 (27.04.00)
(21) International Application Number: PCT/GB99/03420		gle Park, NC 27709 (US). WU, Zhengdong [CN/US]; 1086 King Road, DR218, Malvern, PA 19355 (US).	
(22) International Filing Date: 15 October 1999 (15.10.99)		(74) Agent: LEAROYD, Stephanie, Anne; Glaxo Wellcome plc, Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).	
(30) Priority Data: 9822473.6 16 October 1998 (16.10.98) GB		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(71) Applicants (for all designated States except US): GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB). THE UNIVERSITY OF SOUTH CAROLINA [US/US]; Office of Technology Transfer, Byrnes Building, Suite 501, Columbia, SC 29208 (US).		Published With international search report.	
(72) Inventors; and (75) Inventors/Applicants (for US only): BROWN, Peter, Jonathan [GB/US]; Glaxo Wellcome Inc., Five Moore Drive, Research Triangle Park, NC 27709 (US). CHAPMAN, James, Mood [US/US]; Dept. of Basic Pharmaceutical Sciences, College of Pharmacy, University of South Carolina, Columbia, SC 29208 (US). OPLINGER, Jeffrey, Alan [US/US]; Glaxo Wellcome Inc., Five Moore Drive, Research Triangle Park, NC 27709 (US). STUART, Ludwig, William [US/US]; Glaxo Wellcome Inc., Five Moore Drive, Research Triangle Park, NC 27709 (US). WILLSON, Timothy, Mark [GB/US]; Glaxo Wellcome Inc., Five Moore Drive, Research Trian-		(88) Date of publication of the international search report: 3 August 2000 (03.08.00)	

(54) Title: UREIDO-THIOBUTYRIC ACID DERIVATIVES AS PPAR-AGONISTS



(57) Abstract

Novel compounds of Formula (1) and esters, salts, and physiologically functional derivatives thereof are disclosed. Methods for preparing and using the compounds are also disclosed. Many of these compounds are selective activators of PPAR alpha. The compounds are particularly useful for treating obesity.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China			PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 99/03420

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07C323/62 A61K31/17 C07D295/135

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07C C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 95 18533 A (THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA) 13 July 1995 (1995-07-13) cited in the application page 5, line 15-22	1
A	WO 98 43081 A (LIGAND PHARMACEUTICALS) 1 October 1998 (1998-10-01) the whole document	1
P,X	P.J.BROWN ET AL.: "A Ureido-Thiobutyric Acid (GW9578)" J. MED. CHEM., vol. 42, no. 19, 9 April 1999 (1999-04-09), pages 3785-3788, XP002128791 the whole document	1-16

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

26 January 2000

Date of mailing of the international search report

14 - 04 - 2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Goetz, G

INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB 99/03420

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 10-13 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 99/03420

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9518533	A	13-07-1995	NONE	
WO 9843081	A	01-10-1998	AU 6773598 A	20-10-1998